Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells $1,600,786.80 in Stock

Key Points

• Kiniksa Pharmaceuticals Director Thomas Malley sold 49,407 shares at $32.40 per share, totaling approximately $1.6 million, significantly reducing his ownership in the company by 79.75%.
• After recent trades, Kiniksa's stock price dipped 1.1% to $33.28, though it has fluctuated between a one-year low of $17.82 and a high of $33.98.
• Analysts have increased their price targets for Kiniksa, with Jefferies raising their target from $45.00 to $54.00 and a consensus rating of "Buy" across multiple analysts.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director Thomas Malley sold 49,407 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $32.40, for a total transaction of $1,600,786.80. Following the completion of the transaction, the director owned 12,546 shares in the company, valued at approximately $406,490.40. This trade represents a 79.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Thomas Malley also recently made the following trade(s):

• On Wednesday, August 13th, Thomas Malley sold 50,129 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.32, for a total transaction of $1,670,298.28.
• On Thursday, August 14th, Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97.

Kiniksa Pharmaceuticals International Trading Down 1.7%

NASDAQ KNSA traded down $0.57 during trading hours on Tuesday, reaching $33.15. 371,536 shares of the company's stock were exchanged, compared to its average volume of 712,135. The firm has a fifty day moving average of $29.49 and a 200-day moving average of $25.23. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $34.55. The stock has a market cap of $2.46 billion, a PE ratio of 828.96 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 492,630 shares of the company's stock valued at $9,744,000 after buying an additional 9,654 shares during the period. Wells Fargo & Company MN increased its stake in shares of Kiniksa Pharmaceuticals International by 54.7% in the 4th quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock valued at $417,000 after acquiring an additional 7,463 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at about $3,955,000. Barclays PLC raised its position in shares of Kiniksa Pharmaceuticals International by 11.2% in the 4th quarter. Barclays PLC now owns 71,896 shares of the company's stock valued at $1,423,000 after acquiring an additional 7,267 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Kiniksa Pharmaceuticals International by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock worth $15,262,000 after acquiring an additional 29,300 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on KNSA. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Jefferies Financial Group increased their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Finally, Wedbush reissued an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Six research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.